RSS Novo Nordisk's Ozempic Gets CHMP's Positive Opinion To Include Kidney Disease Label Update

Currently reading:
 RSS Novo Nordisk's Ozempic Gets CHMP's Positive Opinion To Include Kidney Disease Label Update

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,209
Likes
1,916
Credits
32,769©
Cash
0$
Novo Nordisk A/S (NVO) announced on Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has endorsed an update to the labeling of their weight-loss medication, Ozempic, to include the potential for reducing the risk of kidney disease. This decision arises from the results of the FLOW trial, which evaluated the effects of Ozempic, a weekly administered subcutaneous semaglutide, on chronic kidney disease-related outcomes.

The trial, which was randomized, double-blind, and placebo-controlled, demonstrated that semaglutide at a dose of 1.0 mg lowered the risk of kidney disease by 24%. It also showed an 18% reduction in the risk of major cardiovascular events and a 20% decrease in all-cause mortality.

Novo Nordisk, headquartered in Denmark, has also pursued a similar label expansion in the United States, with an anticipated decision expected in the first half of 2025.

At present, the company's stock is trading at $110.57 on the New York Stock Exchange, reflecting a 1% decrease.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom